Amanda Nickles Fader, MD

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.